|
ERLOTINIB U LIJEČENJU BOLESNIKA S UZNAPREDOVALIM KARCINOMOM PLUĆA NEMALIH STANICA: ISKUSTVO KLINIČKE BOLNICE ZA PLUĆNE BOLESTI »JORDANOVAC« ERLOTINIB IN NON-SMALL CELL LUNG CANCER: EXPERIENCE OF CLINICAL HOSPITAL FOR LUNG DISEASES »JORDANOVAC« SANJA PLEŠTINA, MIROSLAV SAMARŽIJA, STJEPKO PLEŠTINA, NABIL CHALFE, ERVIN ŽULJEVIĆ Deskriptori: Karcinom pluća nemalih stanica – farmakoterapija; Tumori pluća – farmakoterapija; Receptor za epidermalni faktor rasta – antagonisti i inhibitori; Protein-tirozin kinaze – antagonisti i inhibitori; Kinazolini – terapijska upotreba; Inhibitori proteinske kinaze – terapijska upotreba; Protutumorski lijekovi – terapijska upotreba
Sažetak. Inhibitori tirozin-kinaze receptora za epidermalni čimbenik rasta posljednjih su godina doveli do produljenja preživljenja i poboljšanja kvalitete života bolesnika s uznapredovalim karcinomom pluća nemalih stanica, nakon neuspjeha liječenja najmanje jednom linijom kemoterapije. U Klinici za plućne bolesti »Jordanovac« erlotinibom smo liječili 36 bolesnika u III.B i IV. stadiju bolesti. U 4 bolesnika (11%) za liječenja erlotinibom došlo je do potpune regresije mjerljivog tumora, u petero (14%) potvrđena je djelomična regresija tumora, dok je stabilnu bolest imalo 14 bolesnika (39%). Evidentnu kliničku korist primijenjenog liječenja erlotinibom imala su, dakle, ukupno 23 bolesnika, odnosno njih 64%. Podnošljivost liječenja bila je pritom vrlo dobra. Ovi su rezultati prvo hrvatsko iskustvo, a u skladu su s podacima objavljenim u literaturi, unekoliko ih čak i nadmašuju. Primjena erlotiniba velik je napredak u liječenju bolesnika s uznapredovalim karcinomom pluća nemalih stanica u Hrvatskoj.
Descriptors: Carcinoma, non-small cell lung – drug therapy; Lung neoplasms – drug therapy; Receptor, epidermal growth factor – antagonists and inhibitors; Protein-tyrosine kinases – antagonists and inhibitors; Quinazolines – therapeutic use; Protein kinase inhibitors – therapeutic use; Antineoplastic agents – therapeutic use
Summary. Treatment with erlotinib, an inhibitor of the epidermal growth factor receptors, has significantly improved the overall survival rate and quality of life in patients with non-small cell lung cancer who had failed the standard first- or second-line chemotherapy. In Clinical hospital for lung diseases »Jordanovac« a total of 36 patients were treated with erlotinib. The response rate was as follows: in four patients (11%) complete response was achieved, in five (4%) partial response, while fourteen patients (39%) had stable disease. Hence, the evident clinical benefit of treatment with erlotinib was registered in 23 patients (64%) altogether. The treatment was well tolerated and it was not associated with significant toxicity. Our results confirm the antitumour efficacy of erlotinib and show a clear treatment benefit for patients with non-small cell lung cancer in our country. Liječ Vjesn 2007;129:387–390 |
